ACLARION, INC. (ACON) Operating Margin
- Operating margin · 12 months: Value -11592.14%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -11592.14% | Operating income / revenue. Period ending 2026-06-30. $-9.71M ÷ $83.77K × 100 ≈ -11592.14% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -9.71M USD | Operating Income (Loss) |
| Revenue | 83.77K USD | |
| Cost of products and services | (m) | |
| Research and development | 1.18M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-9.71M | $83.77K | (m) | $1.18M | (m) | -11592.14% |
| 2026-03-31 | $-8.55M | $77.88K | (m) | $1.15M | (m) | -10975.24% |
| 2025-12-31 | $-7.05M | $75.73K | (m) | $1.03M | (m) | -9312.55% |
| 2025-09-30 | $-6.87M | $67.48K | (m) | $1.02M | (m) | -10173.85% |
| 2025-06-30 | $-6.33M | $62.95K | (m) | $916.25K | (m) | -10056.89% |
| 2025-03-31 | $-5.73M | $54.60K | (m) | $847.91K | (m) | -10493.70% |
| 2024-12-31 | $-5.51M | $45.72K | (m) | $888.77K | (m) | -12057.23% |
| 2024-09-30 | $-4.83M | $49.29K | (m) | $857.62K | (m) | -9805.77% |
| 2024-06-30 | $-4.70M | $53.95K | (m) | $860.07K | (m) | -8711.11% |
| 2024-03-31 | $-4.97M | $60.05K | (m) | $907.98K | (m) | -8276.75% |
| 2023-12-31 | $-4.88M | $75.40K | (m) | $873.34K | (m) | -6466.48% |
| 2023-09-30 | $-4.69M | $84.13K | (m) | $871.65K | (m) | -5577.40% |
| 2023-06-30 | $-5.16M | $83.28K | (m) | $964.37K | (m) | -6199.49% |
| 2023-03-31 | $-5.97M | $76.89K | (m) | $1.07M | (m) | -7764.19% |
| 2022-12-31 | $-6.10M | $60.44K | (m) | $1.09M | (m) | -10089.53% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-2.95M | $60.29K | (m) | $787.85K | (m) | -4897.89% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |